Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.15
(
-1.19%
)
US TECH 100
23,366.80
(
-1.49%
)
Dow Jones
45,670.16
(
-0.76%
)
Brent Oil
106.99
(
2.45%
)
Bitcoin
69,896.00
(
0.00%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: howabouthemdawgs post# 28048

Tuesday, 05/02/2006 4:06:39 PM

Tuesday, May 02, 2006 4:06:39 PM

Post# of 257262
>Dew, IDIX do the +'s outweigh the -'s? Did you hear anything that soured your view? Sum this up for us non-medical folks.<

I think IDIX is a screaming buy for the reasons I’ve previously posted, and the main value driver is the Telbivudine program in HBV. However, I consider today’s CC, specifically, to be modestly negative due to the revelation of additional challenges for NM283 in the treatment-refractory HCV setting.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today